Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christiane Amendt is active.

Publication


Featured researches published by Christiane Amendt.


Molecular Cancer Therapeutics | 2008

Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate

James D. Orth; Yangzhong Tang; Jade Shi; Clement Loy; Christiane Amendt; Claudia Wilm; Frank Zenke; Timothy J. Mitchison

Kinesin-5 inhibitors (K5I) are promising antimitotic cancer drug candidates. They cause prolonged mitotic arrest and death of cancer cells, but their full range of phenotypic effects in different cell types has been unclear. Using time-lapse microscopy of cancer and normal cell lines, we find that a novel K5I causes several different cancer and noncancer cell types to undergo prolonged arrest in monopolar mitosis. Subsequent events, however, differed greatly between cell types. Normal diploid cells mostly slipped from mitosis and arrested in tetraploid G1, with little cell death. Several cancer cell lines died either during mitotic arrest or following slippage. Contrary to prevailing views, mitotic slippage was not required for death, and the duration of mitotic arrest correlated poorly with the probability of death in most cell lines. We also assayed drug reversibility and long-term responses after transient drug exposure in MCF7 breast cancer cells. Although many cells divided after drug washout during mitosis, this treatment resulted in lower survival compared with washout after spontaneous slippage likely due to chromosome segregation errors in the cells that divided. Our analysis shows that K5Is cause cancer-selective cell killing, provides important kinetic information for understanding clinical responses, and elucidates mechanisms of drug sensitivity versus resistance at the level of phenotype. [Mol Cancer Ther 2008;7(11):3480–9]


Aaps Journal | 2017

Erratum to: Tumor Static Concentration Curves in Combination Therapy

Tim Cardilin; Joachim Almquist; Mats Jirstand; Alexandre Soselly; Christiane Amendt; Samer El Bawab; Johan Gabrielsson

Results: Drug exposure models The parameter value for the cetuximab model should be ke = 0.017h − , ka = 0.44h − , F = 1, and V = 94mL ⋅ kg . The parameter values for the cisplatin model should be ka = 42h − , k10 = 1.3h − , k12 = 3.3h − , k21 = 0.047h − , F = 1, and Vp = 377mL ⋅ kg . Table I In the third column the between-subject variability values should be 10 and 33 (instead of 0.10 and 0.33) In the second column the value of Cov(k_g,V^0) should be changed to 0.017 (instead of 0.13). Appendix 1 The first line should read: “Consider the unperturbed tumor model incorporating natural cell death, with main compartment V1 and damage compartments V2,...,Vn, described by the following system of differential equations” Equation 36: The vectors should be


Archive | 2004

Benzimidazole carboxamides as raf kinase inhibitors

Hans-Peter Buchstaller; Matthias Wiesner; Frank Zenke; Christiane Amendt; Matthias Grell; Christian Sirrenberg


Archive | 2003

Methylene urea derivatives as raf-kinase inhibitors

Hans Peter Buchstaller; Matthias Wiesner; Oliver Schadt; Christiane Amendt; Frank Zenke; Christian Sirrenberg; Matthias Grell; Dirk Finsinger


Archive | 2004

Benzimidazole derivatives as raf kinase inhibitors

Hans-Peter Buchstaller; Dirk Finsinger; Matthias Wiesner; Lars Thore Burgdorf; Christiane Amendt; Matthias Grell; Christian Sirrenberg; Frank Zenke


Archive | 2003

GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS

Hans-Peter Buchstaller; Matthias Wiesner; Oliver Schadt; Christiane Amendt; Frank Zenke; Christian Sirrenberg; Matthias Grell


Archive | 2005

Pyridinamide derivatives as kinase inhibitors

Lars Thore Burgdorf; Hans-Peter Buchstaller; Frank Stieber; Christiane Amendt; Hartmut Greiner; Matthias Grell; Christ an Sirrenberg; Frank Zenke


Archive | 2002

Use of endothelin receptor antogonists for the treatment of tumour diseases

Mathias Osswald; Dieter Dorsch; Werner Mederski; Christiane Amendt; Matthias Grell


Archive | 2005

Pyridinamide derivative as kinase inhibitors

Lars Thore Burgdorf; Hans-Peter Buchstaller; Frank Stieber; Christiane Amendt; Hartmut Greiner; Matthias Grell; Christian Sirrenberg; Frank Zenke


Archive | 2004

Oxamide derivatives useful as raf-kinase inhibitors

Hans-Peter Buchstaller; Matthias Wiesner; Frank Zenke; Christiane Amendt; Matthias Grell; Christian Sirrenberg

Collaboration


Dive into the Christiane Amendt's collaboration.

Researchain Logo
Decentralizing Knowledge